Chronic ceftriaxone treatment rescues hippocampal memory deficit in AQP4 knockout mice via activation of GLT-1

Aquaporin-4 (AQP4) is the predominant water channel protein in the mammalian brain, and is mainly expressed in astrocytes. Besides its important role in water transport across the blood–brain barrier, our present study demonstrated that AQP4 deficiency impaired hippocampal long-term potentiation (LT...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropharmacology 2013-12, Vol.75, p.213-222
Hauptverfasser: Yang, Jun, Li, Ming-Xing, Luo, Yi, Chen, Tao, Liu, Jing, Fang, Peng, Jiang, Bo, Hu, Zhuang-Li, Jin, You, Chen, Jian-Guo, Wang, Fang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aquaporin-4 (AQP4) is the predominant water channel protein in the mammalian brain, and is mainly expressed in astrocytes. Besides its important role in water transport across the blood–brain barrier, our present study demonstrated that AQP4 deficiency impaired hippocampal long-term potentiation (LTP) and hippocampus-dependent memory formation, accompanied by the increase in extracellular glutamate concentration and N-methyl-d-aspartate (NMDA) receptor-mediated currents in hippocampal dentate gyrus (DG) region. The impairment of LTP and memory formation of AQP4 knockout (KO) mice was mediated by the downregulation of glutamate transporter-1 (GLT-1) expression/function, since it can be rescued by β-lactam antibiotic ceftriaxone (Cef), a potent GLT-1 stimulator. These results suggest that AQP4 functions as the modulator of synaptic plasticity and memory, and chronic Cef treatment rescues hippocampal memory deficit induced by AQP4 knockout. •Hippocampal synaptic plasticity in vivo and memory is impaired in AQP4 KO mice.•Cef rescues the deficits of hippocampal LTP and memory in AQP4 KO mice.•Cef inhibits GLT-1 to prevent excessive activation of NMDAR in AQP4 KO mice.
ISSN:0028-3908
1873-7064
DOI:10.1016/j.neuropharm.2013.08.009